With more novel therapies targeting both obesity and T2D in the pipeline, this is only the beginning of our discussion
PlexusDx recommends reviewing your plan's specific rules before year-end
Your journey to optimal wellness is unique, and we're here to support you with expertise and care every step of the way.
Clinical trials of semaglutide in people with type 2 diabetes show that while hypoglycemic events do occur, they are typically mild and manageable when doses of other medications are adjusted appropriately
Nonetheless, there is an ongoing debate over the causative relationship between TMAO and cardiovascular disease, as certain studies have found no connection
[5] Concerns about tirzepatide and bone health arise from several factors: the medication's significant weight loss effects, reduced food intake due to appetite suppression, and the complex relationship between diabetes, obesity, and skeletal health